Future prospects for oncolytic therapy
Open Access
- 21 November 2005
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 24 (52) , 7817-7819
- https://doi.org/10.1038/sj.onc.1209064
Abstract
Viruses have been engineered to replicate selectively in cancer cells, based on a number of innovative principles. Several of these viruses have entered clinical trials and have proven relatively safe, and have shown evidence of efficacy. However, further research is required to enable these agents to function systemically. This might involve attempts to suppress immune responses to virus antigens, and re-targeting of viruses to favor tumor infection and increased potency. When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical oncology,Keywords
This publication has 8 references indexed in Scilit:
- Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivityCancer Cell, 2004
- Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma PathwayJNCI Journal of the National Cancer Institute, 2003
- Intravascular adenoviral agents in cancer patients: Lessons from clinical trialsCancer Gene Therapy, 2002
- Selectively replicating viral vectorsCancer Gene Therapy, 2002
- Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agentsCancer Cell, 2002
- Cancer gene therapy: fringe or cutting edge?Nature Reviews Cancer, 2001
- Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trialGene Therapy, 2001
- An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacyNature Medicine, 2000